Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
8 clinical trials · Condition
◉ Watch Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
| Record | Firm | Date |
|---|---|---|
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis (NCT04878003) | Kartos Therapeutics, Inc. | 2021-04-13 |
| Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis (NCT04217993) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-01-07 |
| Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (NCT03935555) | Samus Therapeutics, Inc. | 2019-08-12 |
| Extended Access of Momelotinib in Adults With Myelofibrosis (NCT03441113) | GlaxoSmithKline | 2018-05-03 |
| Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (NCT02101268) | Sierra Oncology LLC - a GSK company | 2014-06-19 |
Track Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) automatically
Every clearance here is in the API, with alerts when new ones post.